- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
June 10, 2026
To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001
Scrip code: 524632
Sub: Outcome of the meeting of the Board of Directors held on Wednesday, June 10, 2026.
Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and
Disclosure Requirement) Regulation, 2015.
Dear Sir/Madam,
With reference to above subject and in compliance with Regulation 30 of the Securities and
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015,
we hereby submit the outcome of the Meeting of the Board of Director held on today i.e.,
Wednesday, June 10, 2026, at 6.00 p.m. and concluded on 6.50 p.m. inter alia considered and
approved the following:
1. The Board considered and approved the proposal to seek fresh approval of the
shareholders by way of a Special Resolution in terms of Regulation 170(2) of the SEBI
(Issue of Capital and Disclosure Requirements) Regulations, 2018, in respect of the
preferential issue of 46,43,000 Convertible Equity Warrants originally approved by the
shareholders at the Extra-Ordinary General Meeting held on November 01, 2025, for
which in-principle approval from BSE Limited was received vide its letter dated January
09, 2026. Since the allotment of the said warrants could not be completed within the
period prescribed under Regulation 170(1) of the SEBI ICDR Regulations, fresh
approval of the shareholders is required under Regulation 170(2) of the SEBI ICDR
Regulations. Accordingly, the issue price of the warrants shall be re-computed in
accordance with the applicable provisions of Chapter V of the SEBI ICDR Regulations
and the warrants shall be allotted at a price not lower than the higher of (i) X34/- per
warrant, being the issue price approved by the shareholders at the aforesaid Extra-
Ordinary General Meeting, and (i) the price determined pursuant to such re-
computation under the SEBI ICDR Regulations.
CIN : L24231GJ1993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com
----------------Page (0) Break----------------
The Detailed disclosure as re‘quirerd‘undevr R‘eg‘u;lation 30(6) |;eva<; ;n;ith S.cf{éaulé Iil, Par‘f
A, Para A of the SEBI Listing Regulations and the SEBI Circular CIR/CFDICMDI412015
dated 9 September 2015 for preferential issue is attached herewith as an Annexure-
A.
. The Board noted that the Relevant Date for determination of the issue price in
accordance with Chapter V read with Regulation 161 of the SEBI (Issue of Capital and
Disclosure Requirements) Regulations, 2018 shall be Friday, June 05, 2026, being the
trading day immediately preceding Saturday, June 06, 2026, which falls 30 (thirty) days
prior to the date of the Extra-Ordinary General Meeting proposed to be held on July
06, 2026.
. Approved the Notice convening the Extra-Ordinary General Meeting of the Company
to be held on Monday, July 06, 2026 through Video Conferencing/Other Audio-Visual
Means.
. Appointed Ms. Rupal Patel, Practicing Company Secretary, as Scrutinizer for
conducting the voting process of the Extra-Ordinary General Meeting in a fair and
transparent manner.
The meeting of the Board of Directors commenced at 6:00 P.M. and concluded at 6:50 P.M.
Kindly take the same on your records.
Thanking you,
Yours faithfully,
For, Shukra Pharmaceuticals Limite
forgeet
Arpita Kabra
Company Secretary
ACS No. A50258
CIN : L24231GJ1993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com
----------------Page (1) Break----------------
Annexure- A
SN | Particulars Details
1 | Types of Securities
proposed to be issued
Convertible equity warrants carrying a right to subscribe 1 (one)
Equity Share per warrant.
2 | Types of Issuances Preferential allotment on a private placement basis in accordance
with the provisions of the Companies Act, 2013 and the rules made
thereunder and SEBI (Issue of Capital and Disclosure Requirements)
Regulations, 2018, as amended (“ICDR Regulations”) and other
applicable laws.
(Approximately)
3 | Total number of securities
proposed to be issued or
the total amount for which
the securities will be issued
Cl
46,43,000 (Forty-Six Lacs Forty Three Thousand) Convertible Equity
Warrants (hereinafter referred to as “Warrants”) on preferential
basis (“Preferential Offer”) to the Promoter category as mentioned
below (“Warrant Holder”/” Proposed Allottee”) for cash
consideration at a revised price of Rs.35.56/-, aggregating upto
Rs.16,51,05,080/- (Rupees Sixteen Crore Fifty-One Lakhs Five
Thousand Eighty Only)
The price of the warrants has been determined in accordance with
the ICDR Regulations. The preferential issue will be undertaken for
cash consideration.
In terms of Regulation 170(2) of the SEBI (Issue of Capital and
Disclosure Requirements) Regulations, 2018, fresh approval of the
shareholders is being sought and the Company has undertaken a
fresh pricing exercise based on the Relevant Date of June 06, 2026.
Accordingly, the revised issue/exercise price of each Convertible
Equity Warrant has been determined at Rs.35.56 per warrant.
An amount equivalent to 25% of the original warrant issue price has
already been received from the proposed allottees at the time of
allotment of warrants pursuant to the earlier shareholders'
approval and in-principle approval granted by BSE Limited.
Upon obtaining fresh shareholders' approval under Regulation
170(2) of the SEBI ICDR Regulations, the amount already received
shall continue to be appropriated towards the subscription
consideration of the warrants. The balance consideration, together
with any differential amount arising on account of the revised issue
price, shall be payable at the time of exercise of the warrants in
accordance with the applicable provisions of the SEBI ICDR
N°Et54591 G11993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com
----------------Page (2) Break----------------
SN | Particulars Details
The price of the warrants and the number of Equity Shares to be
allotted on conversion of warrants shall be subject to appropriate
adjustments as permitted under applicable laws.
4 | Name of the Investors As per Schedule -1
5 | Post allotment of
securities- outcome of the | The equity shares are proposed to be allotted to Promoters. Details
subscription of the shareholding of Investors in the Company, prior to and after
the proposed Preferential Issue, are as under:
As per Schedule - |
6 | Issue Price Rs.35.56/- (Thirty Five Rupees Fifty-Six Paisa Only) per warrant
7 | Number of Investor 5
8 | In case of convertibles — | The tenure of the warrants shall not exceed 18 (eighteen) months
intimation on conversion | from the date of allotment. Each warrant shall carry a right to
of securities or on lapse of | subscribe 1 (one) Equity Share per warrant, which may be exercised
the tenure of the in one or more tranches during the period commencing from the
instrument; date of allotment of warrants until the expiry of 18 (eighteen)
months from the date of allotment of the warrants.
In the event that, a warrant holder does not exercise the warrants
within a period of 18 (Eighteen) months from the date of allotment
of such warrants, the unexercised warrants shall lapse and the
amount paid by the warrant holders on such Warrants shall stand
forfeited by the Company.
9 | Any cancellation or Not Applicable
termination of proposal
for issuance of securities
including reasons thereof.
CIN : L24231GJ1993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com
----------------Page (3) Break----------------
Schedule -1
Sr. Name of Pre issue Addition Post issue shareholding
No. shareholders shareholding
No. of equity | Perc | Addition No. of Percentage
Category : Promoter | shares held enta shares Post | of total
ge capital holding
(%) (post
diluted) (%)
ANAR JAYESHBHAI 43,60,000 | 1.00 5,00,000 48,60,000 1.10
1 | PATEL
DAKSHESH 43,60,000 | 1.00 5,00,000 48,60,000 110
RAMESHCHANDRA
2 | SHAH
ANAR PROJECT 8,22,40,000 | 18.78 | 12,35,000 | 8,34,75,000 18.86
3 | PRIVATE LIMITED
PARSHVA TEXCHEM 7,51,75,600 | 17.17 | 12,35,000 | 7,64,10,600 17.27
4 | INDIA PRIVATE LTD.
NAVKAR SURGICAL 5,16,00,000 | 11.78 | 11,73,000 | 5,27,73,000 11.93
5 | GUJARAT LIMITED
Total 21,77,35,600 | 49.73 | 46,43,000 | 22,23,78,600 50.25
For, Shukra Pharmaceuticals Limited
Arpita Kabr:
Company Secretal
ACS No. A50258
CIN : L24231GJ1993PLC019079
Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com
----------------Page (4) Break----------------